Yuimedi

The company's core business revolves around a platform that automates the cleansing, standardization, and aggregation of clinical datasets. Initially focused on the Japanese market, Yuimedi developed "Yuicleaner," a no-code, AI-based software designed for cleansing sensitive medical data. This tool enables users to trace data transformations, ensuring data quality control without requiring programming knowledge. The business model targets healthcare researchers, institutions like university hospitals, and life sciences organizations such as pharmaceutical companies. By providing these tools, Yuimedi facilitates the creation of usable Real World Data (RWD) from sources like electronic medical records, which can accelerate research and drug development.

Building on its experience in Japan, Yuimedi is expanding into the U.S. market with a focus on AI-powered solutions. The company established a U.S. subsidiary, Yuimedi, Corp., in Delaware on January 1, 2024, with a business location in Boston. In the U.S., the company is developing "YuiQuery," a generative AI tool that allows healthcare professionals to extract data and insights using natural language prompts, likened to a 'ChatGPT for physicians'. This product aims to streamline operations and enable faster, data-driven decisions for hospitals and pharmaceutical companies. The company generates revenue through its software and services and has attracted significant investment, including a pre-series A funding round of 450 million yen and an additional 400 million yen in a subsequent round. Yuimedi has participated in several accelerator programs, including the Alchemist Accelerator and was selected for the Google for Startup Women Founders Fund.